Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors

21 juli 2026 bijgewerkt door: Jinsong Wu, Huashan Hospital

AI-Assisted Presurgical MRI Molecular Subtyping for Pediatric Brain Tumors: A Single-Center Ambispective Clinical Cohort Study

This multicenter observational cohort study aims to develop and validate an artificial intelligence (AI)-assisted diagnostic system for preoperative molecular subtyping of pediatric brain tumors using routine magnetic resonance imaging (MRI). The study will include seven major pediatric brain tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor (AT/RT), intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.

The study includes a retrospective cohort for model development and internal/external validation, and a prospective cohort for further validation. Retrospective data will be collected from pediatric patients who underwent first surgical treatment between January 1, 2020 and December 31, 2025. Prospective enrollment will begin on July 15, 2026, with an anticipated sample size of 150 participants. The AI system will analyze preoperative MRI sequences, including T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR images, to predict key molecular markers and integrated diagnostic categories. The primary objective is to evaluate the diagnostic performance of the AI system for prespecified molecular prediction tasks using postoperative histopathology and molecular testing as the reference standard. Secondary objectives include assessing agreement with integrated diagnosis, comparing performance against blinded radiologists, and exploring prognostic associations of AI-predicted subgroups.

Studie Overzicht

Gedetailleerde beschrijving

Pediatric brain tumors are the most common solid tumors in children and represent a highly heterogeneous group of diseases with marked variation in histology, molecular alterations, anatomic location, treatment response, and prognosis. Several molecular features, including H3K27M mutation, BRAF V600E mutation, ZFTA fusion, SMARCB1 loss, CTNNB1 mutation, and TP53 alteration, are clinically important for diagnostic classification, risk stratification, prognosis assessment, and treatment planning. However, most molecular characterization currently depends on postoperative tissue-based testing, and noninvasive preoperative prediction remains limited.

This study is designed to evaluate an AI-assisted MRI-based diagnostic system for pediatric brain tumors in a real-world multicenter observational setting. The study will include seven target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors. The retrospective component will collect multimodal data, including clinical variables, preoperative MRI, pathology reports, molecular testing results, treatment information, and follow-up data, from eligible pediatric patients treated from January 1, 2020 through December 31, 2025. The prospective component will consecutively enroll eligible patients from July 15, 2026 onward for additional validation of model performance.

Preoperative MRI data will be preprocessed using standardized procedures, including bias field correction, skull stripping, isotropic resampling, and intensity normalization. The AI model will be developed to support classification of tumor type and prediction of key molecular subtypes/markers from presurgical MRI. Model performance will be evaluated using postoperative pathology and molecular testing as the reference standard. The primary endpoint is the area under the receiver operating characteristic curve (AUC) for prespecified molecular prediction tasks. Secondary analyses will evaluate agreement between AI output and integrated final diagnosis, comparative performance against blinded radiologists on independent test sets, multiclass tumor classification performance, biomarker-specific sensitivity and specificity, and progression-free survival stratified by AI-predicted subgroup.

This study is observational and is not intended for medical device registration. Biospecimen banking is not a registration objective of this study.

Studietype

Observationeel

Inschrijving (Geschat)

1400

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Pediatric patients with suspected primary brain tumors who undergo first surgical treatment at participating centers and whose postoperative pathology confirms one of seven predefined tumor categories.

Beschrijving

Inclusion Criteria:

  • Age younger than 18 years at the time of index surgery.
  • Evaluated at a participating study center and scheduled for first surgical treatment of a suspected target pediatric brain tumor.
  • Preoperative brain MRI available before surgery, including at minimum T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR sequences in DICOM format; MRI preferably performed within 7 days before surgery and before biopsy or tumor-directed therapy.
  • Postoperative histopathology confirming one of the following target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, or choroid plexus tumors.
  • For the prospective cohort, written informed consent provided by a parent or legal guardian, with child assent obtained when appropriate according to age, understanding, and local ethics requirements.

Exclusion Criteria:

  • Postoperative pathology confirming a non-target tumor type.
  • Recurrent tumor, repeat surgery, or prior tumor-directed surgery before the index surgery.
  • Preoperative MRI of inadequate quality for analysis, including severe motion artifact, severe susceptibility/metal artifact, or incomplete field of view.
  • Prior biopsy, radiotherapy, chemotherapy, or other tumor-directed treatment before the index preoperative MRI that is judged to substantially affect imaging interpretation.
  • Concurrent malignant disease other than the target brain tumor.
  • Inability to comply with follow-up requirements in the prospective cohort, in the investigator's judgment, because of severe comorbidity or other practical limitations.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Retrospective Cohort
Pediatric patients younger than 18 years who underwent first surgical treatment for one of the target brain tumors between January 1, 2020 and December 31, 2025, with available preoperative MRI and postoperative pathological confirmation. Data from this cohort will be used for model development and validation.
Prospective Cohort
Consecutively enrolled pediatric patients younger than 18 years meeting eligibility criteria from July 15, 2026 onward. Data from this cohort will be used for prospective validation of AI diagnostic performance.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Area Under the Receiver Operating Characteristic Curve (AUC) for MRI-Based Prediction of Prespecified Molecular Markers
Tijdsspanne: Assessed at final model evaluation using all eligible retrospective cases collected from January 1, 2020 through December 31, 2025 and all eligible prospectively enrolled cases with available reference-standard data collected from July 15, 2026 through D
Diagnostic discrimination of the AI-assisted system for binary prediction of prespecified key molecular markers or molecular subtypes from preoperative MRI, using postoperative histopathology and molecular testing as the reference standard. AUC values and 95% confidence intervals will be calculated for each prespecified molecular prediction task.
Assessed at final model evaluation using all eligible retrospective cases collected from January 1, 2020 through December 31, 2025 and all eligible prospectively enrolled cases with available reference-standard data collected from July 15, 2026 through D

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Agreement Between AI-Based Diagnosis and Integrated Final Diagnosis
Tijdsspanne: Assessed at final diagnostic adjudication for each eligible participant from study start on July 15, 2026 through study completion on December 30, 2029, including retrospective cases with complete reference-standard data.
Agreement between AI-predicted diagnostic output based on preoperative MRI and the integrated final diagnosis established from imaging, postoperative histopathology, and molecular testing. Agreement will be quantified using Cohen's kappa coefficient.
Assessed at final diagnostic adjudication for each eligible participant from study start on July 15, 2026 through study completion on December 30, 2029, including retrospective cases with complete reference-standard data.
Comparative Diagnostic Performance of the AI System Versus Blinded Radiologists
Tijdsspanne: Assessed at blinded reader evaluation after completion of dataset curation and test set locking, anticipated by December 30, 2029.
Comparison of sensitivity, specificity, accuracy, and AUC between the AI system and radiologists blinded to pathology and molecular results on a predefined independent test dataset.
Assessed at blinded reader evaluation after completion of dataset curation and test set locking, anticipated by December 30, 2029.
Macro-Average AUC for Seven-Class Tumor Classification
Tijdsspanne: Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Macro-average area under the receiver operating characteristic curve for classification of the seven target pediatric brain tumor categories.
Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Weighted F1 Score for Seven-Class Tumor Classification
Tijdsspanne: Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Weighted F1 score of the AI system for multiclass classification across glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.
Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Sensitivity and Specificity for Prediction of Key Molecular Biomarkers
Tijdsspanne: Assessed at final model evaluation using cases with complete biomarker reference-standard results through December 30, 2029.
Sensitivity and specificity of the AI system for prediction of tumor-specific biomarkers, including but not limited to H3K27M mutation, BRAF V600E mutation, ZFTA fusion, SMARCB1 loss, CTNNB1 mutation, and TP53 alteration, depending on tumor type and data availability.
Assessed at final model evaluation using cases with complete biomarker reference-standard results through December 30, 2029.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

15 juli 2026

Primaire voltooiing (Geschat)

30 december 2029

Studie voltooiing (Geschat)

30 december 2029

Studieregistratiedata

Eerst ingediend

8 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

8 juli 2026

Eerst geplaatst (Werkelijk)

14 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

23 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

21 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren